NRXBF (NurExone Biologic) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NurExone Biologic's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. NurExone Biologic's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.03 Mil. NurExone Biologic's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

NurExone Biologic Debt-to-Revenue Historical Data

The historical data trend for NurExone Biologic's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Debt-to-Revenue Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Revenue

N/A

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial									N/A	N/A	N/A	N/A	N/A

Competitive Comparison of NurExone Biologic's Debt-to-Revenue

For the Biotechnology subindustry, NurExone Biologic's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

NurExone Biologic Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NurExone Biologic's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.018	+	0.002)	/	N/A
	=	N/A

NurExone Biologic's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0.031)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

NurExone Biologic Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.